BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14517486)

  • 21. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen assay by means of the lysis time method.
    Berg W; Korsan-Bengtsen K; Ygge J
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
    Ries M; Zenker M; Gaffney PJ
    Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.
    Suelves M; López-Alemany R; Lluís F; Aniorte G; Serrano E; Parra M; Carmeliet P; Muñoz-Cánoves P
    Blood; 2002 Apr; 99(8):2835-44. PubMed ID: 11929773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteration of fibrin network by activated protein C.
    Gruber A; Mori E; del Zoppo GJ; Waxman L; Griffin JH
    Blood; 1994 May; 83(9):2541-8. PubMed ID: 8167339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombospondin is a slow tight-binding inhibitor of plasmin.
    Hogg PJ; Stenflo J; Mosher DF
    Biochemistry; 1992 Jan; 31(1):265-9. PubMed ID: 1531022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
    Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intersection of Coagulation and Fibrinolysis by the Glycosylphosphatidylinositol (GPI)-Anchored Serine Protease Testisin.
    Buzza MS; Pawar NR; Strong AA; Antalis TM
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
    Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
    Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
    Wu JH; Siddiqui K; Diamond SL
    Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins.
    Jian JW; Chiu WC; Chang HT; Hsu PH; Huang CC
    Anal Chim Acta; 2013 Apr; 774():67-72. PubMed ID: 23567118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding.
    Rahman MN; Petrounevitch V; Jia Z; Koschinsky ML
    Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom.
    Cheng AC; Tsai IH
    Biochim Biophys Acta; 2014 Jan; 1840(1):153-9. PubMed ID: 23999090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.